A novel study on the impact of supplemental oxygen prescription in pulmonary fibrosis entitled “Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis” was published in the journal BMC Pulmonary Medicine by Amanda Belkin, part of Dr. Jeffrey J Swigris’group from Autoimmune Lung Center and Interstitial Lung…
News
A new study entitled “Lung fibrotic tenascin-C up regulation is associated with other extracellular matrix proteins and induced by TGFβ1” and published in BMC Pulmonary Medicine journal suggests that the Tenascin C protein is a glycoprotein that may be relevant for fibroblastic foci activity and fibrosis…
A new study entitled “Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood” published in October issue of BMC Genomics reports that the diagnosis of sporadic idiopathic pulmonary fibrosis from peripheral blood samples by identifying a functional genetic signature.The new findings could have…
A broad perspective of idiopathic pulmonary fibrosis causes were recently discussed in a wide-ranging featured lecture published on AJMC entitled “Idiopathic Pulmonary Fibrosis: Biomarkers and New Treatment Options” by expert in idiopathic pulmonary fibrosis Steven K. Huang, MD at the 2014 American College of Chest…
Ofev (nintedanib) capsules, a new drug treatment for idiopathic pulmonary fibrosis (IPF) developed by Boehringer Ingelheim Pharmaceuticals, Inc. is already being made available in select pharmacies throughout the United States with a prescription. The announcement of Ofev’s availability was recently made by the company, and…
MediciNova, Inc.’s idiopathic pulmonary fibrosis (IPF) drug candidate MN-001 (tipelukast) was recently granted orphan drug status by the US Food and Drug Administration. As a result, MediciNova will have exclusive rights to market MN-001 to treat patients with IPF, should it be approved following clinical trials. “We are very pleased…
The United States just received the first two treatments for idiopathic pulmonary fibrosis, however, while Boehringer Ingelheim GmbH‘s therapy, OFEV (nintedanib), will cost $96,000 per year, its competitor, Esbriet (pirfenidone) from InterMune/Roche Holding AG won’t cost much less, according to a news report from…
A research article published this month in the journal BMC Genomics finds that peripheral blood biomarkers might improve accuracy in diagnosing idiopathic pulmonary fibrosis (IPF) — which the National Heart, Lung, and Blood Institute describes as a disease in which tissue deep in the lungs…
ProMetic Life Sciences has just announced that it will begin research on the application of their lead pipeline product for pulmonary fibrosis, PBI-4050, in idiopathic pulmonary fibrosis (IPF), an unusual type of PF that leads to spontaneous lung scarring and is estimated to affect over 130,000 Americans. Every…
The U.S. Food and Drug Administration (FDA) recently approved two drugs that are the first therapies specifically directed for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States, Esbriet (pirfenidone), from InterMune, Inc., and OFEV (nintedanib), from…
